# A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

> **NCT02795767** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 88 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Emicizumab

## Key facts

- **NCT ID:** NCT02795767
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-22
- **Primary completion:** 2018-04-30
- **Final completion:** 2020-11-11
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2021-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02795767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02795767, "A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02795767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*